Merck Serono, the biopharmaceutical division of Merck KGaA, of Darmstadt, Germany, reported the start of an international phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1).